Award information

2025 Winner

Zealand Pharma A/S

EMA25_W011-Transac_Thumb.jpg

Download hi-res image

Picture shows, left to right;
Nina Hossain, awards presenter; Alexandra Pygall Partner, Head of Life Sciences and Healthcare, Stephenson Harwood (award sponsor); Christina Sonnenborg Bredal, EVP, Chief People Officer, Zealand Pharma (award winner); Ivan Moller, EVP, Chief Operating Officer, Zealand Pharma (award winner); Melody A. Carey, President & Chief Executive Officer, Rx Communications Group, LLC (Mainline sponsor); and Neil Shah, Executive Director, Content & Strategy, Edison Group (Mainline sponsor).

2025 Shortlist

  • BioVersys AG
  • NewAmsterdam Pharma Company NV
  • Oculis Holding AG
  • Optima Health plc
  • Vicore Pharma Holding AB
  • Zealand Pharma A/S

Criteria 

This award recognises a significant capital market transaction during our period under review. The capital market transaction could be an IPO or a follow-on financing; it would be significant in scope and transformational in nature and would materially enhance the prospects for the business in the short, medium and long term.

In deciding the shortlist and eventual winner, the Voting Panel will take into account the amount raised, stock price performance and the quality of the share register.